DaVita Inc
DVA: XNYS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$734.00 | Ymmvnn | Ppznfngnt |
DaVita Faces Challenges in Q1 but Maintains its 2022 and Preliminary 2023 Outlook; No FVE Change
Shares of DaVita declined around 6% in after-hours trading after the company reported first-quarter results that were weaker than market expectations. However, given the omicron variant surge during the period and labor challenges permeating the healthcare sector, we weren't terribly surprised with the weak results. Additionally, management maintained its guidance for the full year and noted that treatment volumes even started increasing in March and April.